Your browser doesn't support javascript.
loading
The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England.
Lunt, Rachel; Quinot, Catherine; Kirsebom, Freja; Andrews, Nick; Skarnes, Catriona; Letley, Louise; Haskins, Donna; Angel, Catriona; Firminger, Skye; Ratcliffe, Kay; Rajan, Shelina; Sherridan, Angela; Ijaz, Samreen; Zambon, Maria; Brown, Kevin; Ramsay, Mary; Bernal, Jamie Lopez.
Afiliação
  • Lunt R; UK Health Security Agency, London, United Kingdom. Electronic address: rachel.lunt@ukhsa.gov.uk.
  • Quinot C; UK Health Security Agency, London, United Kingdom.
  • Kirsebom F; UK Health Security Agency, London, United Kingdom.
  • Andrews N; UK Health Security Agency, London, United Kingdom; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Skarnes C; UK Health Security Agency, London, United Kingdom.
  • Letley L; UK Health Security Agency, London, United Kingdom.
  • Haskins D; UK Health Security Agency, London, United Kingdom.
  • Angel C; UK Health Security Agency, London, United Kingdom.
  • Firminger S; UK Health Security Agency, London, United Kingdom.
  • Ratcliffe K; UK Health Security Agency, London, United Kingdom.
  • Rajan S; UK Health Security Agency, London, United Kingdom.
  • Sherridan A; UK Health Security Agency, London, United Kingdom.
  • Ijaz S; UK Health Security Agency, London, United Kingdom.
  • Zambon M; UK Health Security Agency, London, United Kingdom; NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, United Kingdom.
  • Brown K; UK Health Security Agency, London, United Kingdom.
  • Ramsay M; UK Health Security Agency, London, United Kingdom; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Bernal JL; UK Health Security Agency, London, United Kingdom; NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom; NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, United Kingdo
J Infect ; 88(1): 21-29, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37926118
ABSTRACT
Vaccination status and the SARS-CoV-2 variant individuals are infected with are known to independently impact viral dynamics; however, little is known about the interaction of these two factors and how this impacts viral dynamics. Here we investigated how monovalent vaccination modified the time course and viral load of infections from different variants. Regression analyses were used to investigate the impact of vaccination on cycle threshold values and disease severity, and interval-censored survival analyses were used to investigate the impact of vaccination on duration of positivity. A range of covariates were adjusted for as potential confounders and investigated for their own effects in exploratory analyses. All analyses were done combining all variants and stratified by variant. For those infected with Alpha or Delta, vaccinated individuals were more likely to report mild disease than moderate/severe disease and had significantly shorter duration of positivity and lower viral loads compared to unvaccinated individuals. Vaccination had no impact on self-reported disease severity, viral load, or duration if positivity for those infected with Omicron. Overall, individuals who were immunosuppressed and clinically extremely vulnerable had longer duration of positivity and higher viral loads. This study adds to the evidence base on disease dynamics following COVID-19, demonstrating that vaccination mitigates severity of disease, the amount of detectable virus within infected individuals and reduces the time individuals are positive for. However, these effects have been significantly attenuated since the emergence of Omicron. Therefore, our findings strengthen the argument for using modified or multivalent vaccines that target emerging variants.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 4_TD Problema de saúde: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis / 4_pneumonia Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Infect Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 4_TD Problema de saúde: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis / 4_pneumonia Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Infect Ano de publicação: 2024 Tipo de documento: Article
...